| Pre-screening | Baseline | Randomisation | follow-up | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
VISIT | Â | 1A | 1B | 1C | Â | 2 | 3 | 4 | 5 | 6A | 6B | 6C | 7 |
assessments | Within 24 hours of AMI | 7 to 10 days post AMI | Day 0 |  | Week 4 (+/− 7 days) | Week 8 (+/− 7 days) | Week 12 (+/− 7 days) | Week 24 (+/− 7 days) | Week 52 (+/− 7 days) | Week 53 (+/− 7 days) | |||
Identification and initial approach (including provision of PIS) | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Eligibility criteria checked | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Written informed consentǂ |  | X |  |  |  |  |  |  |  |  |  |  |  |
Physical examination (height ****, weight, BP, pulse) | Â | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | X | Â |
Venepuncture | Â | X* | Â | Â | Â | X** | X** | X** | X** | Â | Â | X* | Â |
Clinical history (medical history, medication list) | Â | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Questionnaires (SF12, MLWHFQ, CES-D) completed | Â | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | X | Â |
Safety checks (ECG, pulse oximetry and NYHA assessment | Â | X | Â | Â | Â | X | X | X | X | Â | Â | X | Â |
Cardiac MRI | Â | Â | X | Â | Â | Â | Â | Â | Â | X | Â | Â | Â |
EndoPat, Badimon chamber, VerifyNow and TEG analysis | Â | Â | Â | X | Â | Â | Â | Â | Â | Â | X | Â | Â |
Randomisation (after written informed consent obtained) and study drug dispensation | Â | Â | Â | Â | X # | Â | Â | Â | Â | Â | Â | Â | Â |
Study medication prescribed and dispensed (following LT4 dose assessment at visits 2 to 5 only) | Â | Â | Â | Â | Â | X | X | X | X | Â | Â | Â | Â |
Study medication compliance checks | Â | Â | Â | Â | Â | X | X | X | X | Â | Â | X | Â |
Concomitant medication | Â | Â | Â | Â | Â | X | X | X | X | Â | Â | X | Â |
Adverse events | Â | Â | Â | Â | Â | X | X | X | X | Â | Â | X | X |
Serious adverse events | Â | Â | Â | Â | Â | X | X | X | X | Â | Â | X | X |